ORTHOPEDIATRICS CORP (KIDS) Form 8-K — Oct 27, 2026
OrthoPediatrics reported record Q3 2026 revenue of $72.7 million, up 19% year-over-year, and raised its full-year 2026 revenue guidance to $270.0-$273.0 million from $265.0-$269.0 million. The company nearly halved its net loss to $5.9 million ($0.25/share) from $11.8 million a year ago, achieved record adjusted EBITDA of $6.9 million, and generated positive free cash flow of $1.6 million — a $5.0 million improvement versus prior year. Growth was broad-based across Trauma & Deformity (+19%) and Scoliosis (+18%), aided by new product launches including the 3P Hip System full market release and FDA-cleared PNP Retrograde.
Key figures
- Revenue
- 72700000
- Guidance
- FY2026 revenue raised to $270.0-$273.0 million from $265.0-$269.0 million (14-16% growth); ~$25.0M adjusted EBITDA; breakeven free cash flow expected
- Revenue Yoy
- 19%
- Total Assets
- 509087000
- Cash Position
- 44900000
- Shares Outstanding
- 26115126
- Gross margin
- 74%
- Us revenue q3
- 57900000
- Free cash flow q3
- 1600000
- Adjusted ebitda q3
- 6900000
- Children helped q3
- nearly 42,000
- Scoliosis revenue q3
- 19200000
- Weighted avg shares q3
- 24153621
- Intangible impairment q3
- 611000
- International revenue q3
- 14800000
- Trauma deformity revenue q3
- 52600000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.